Antinociceptive effects of stimulation of discrete sites in the rat hypothalamus: evidence for the participation of the lateral hypothalamus area in descending pain suppression mechanisms.
The sites in the rat hypothalamus where microinjection of morphine (5 micrograms/0.5 microliters) or electrical stimulation depresses the tail withdrawal reflex to noxious heating of the skin were examined. Among other hypothalamic sites found to be sensitive to morphine or to an electrical stimulus, the posterior part of the lateral hypothalamic area (LHA) was the only portion of the hypothalamus that was strongly sensitive to both manipulations. A 15-sec period of 35 microA sine-wave stimulation of the LHA significantly increased the latency of the tail reflex for periods up to 30 min. The effects of intraperitoneal administration of antagonists to opioids (naloxone), 5-hydroxytryptamine (methysergide), noradrenaline (phenoxybenzamine), dopamine (haloperidol), and acetylcholine (atropine and mecamylamine) on the antinociceptive effects of LHA stimulation were also examined. Naloxone, methysergide, and atropine (all given at doses of 0.5 and 1.0 mg/kg) attenuated the effects of LHA stimulation in a dose-dependent manner. Phenoxybenzamine but not haloperidol (both at the dose of 1.0 mg/kg), was also effective but dose-dependent curves could not be constructed. Mecamylamine (1.0 mg/kg) reduced the duration but not the peak effect of stimulating the LHA. We conclude that antagonism at the level of opioid, serotonergic, adrenergic, and muscarinic cholinergic receptors, but not dopamine or nicotinic cholinergic receptors, reduces the antinociceptive effects of LHA stimulation. This may imply that antinociception evoked from the LHA depends on the activation of descending pathways that relay in the mesencephalic periaqueductal gray matter and then in the nucleus raphe magnus and/or nucleus reticularis paragigantocellularis.
Franco
A C
AC
Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto,Universidade de São Paulo, Brasil.
Prado
W A
WA
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000698:Analgesia; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004558:Electric Stimulation; D006220:Haloperidol / Q000494:pharmacology; D007026:Hypothalamic Area, Lateral / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D008784:Methysergide / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D010146:Pain / Q000503:physiopathology*; D010643:Phenoxybenzamine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012702:Serotonin Antagonists / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000701:Analgesics, Opioid; D018492:Dopamine Antagonists; D018727:Muscarinic Antagonists; D009292:Narcotic Antagonists; D018733:Nicotinic Antagonists; D012702:Serotonin Antagonists; D010643:Phenoxybenzamine; D009270:Naloxone; D008464:Mecamylamine; D009020:Morphine; D001285:Atropine; D006220:Haloperidol; D008784:Methysergide